Biocon Biologics Completes Integration of acquired Biosimilars Business in 70+ Emerging Markets Nations

Biocon Biologics Ltd (BBL) said that it has completed the integration of the acquired biosimilars business in over 70 countries in Emerging Markets, which will take effect on July 1, 2023, enhancing the company's scale and breadth. Following the completion of the transaction in November 2022, this is the first wave of nations where Viatris' businesses have been entirely migrated to Biocon Biologics.

A solid integration strategy ensured a smooth shift of partners, people, systems, and procedures between these countries. The existing commercialised portfolio of biosimilars, including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, managed by Viatris in these markets, is now a part of Biocon Biologics’ commercial organisation. The company will work with existing and new partners to expand its footprint and strengthen its business presence in these countries. "The successful integration of Viatris' biosimilars business to Biocon Biologics in over 70 countries is a significant milestone and marks the beginning of the transition process," said Shreehas Tambe, CEO & Managing Director, Biocon Biologics.

Biocon Biologics will now manage commercial operations in these markets, expanding patient access with our differentiated range of high-quality biosimilars in collaboration with our partners. Susheel Umesh, Chief Commercial Officer - Emerging Markets, Biocon Biologics said, “The transitioning of these 70+ Emerging Markets to Biocon Biologics from Viatris marks the first phase of the business integration plan charted out for the acquired business. This will allow Biocon Biologics to meaningfully expand the geographic reach of the existing biosimilars portfolio and future pipeline into growth markets where Viatris has existing sales infrastructure and local market expertise.

Working closely with key stakeholders in these markets will allow us to ensure reliable supplies of our biosimilars for those who need them the most while enabling us to capitalise on the rapidly expanding global biosimilars opportunity.” By expanding access to cost-effective biosimilars, Biocon Biologics seeks to facilitate the achievement of Target 3.4 of the UN Sustainable Development Goals SDGs by 2030 – ie; reduce premature mortality from non-communicable diseases by one-third through prevention and treatment.